Dr. Roger M. Perlmutter, M.D., Ph.D., has been an Executive Vice President at Merck & Co., Inc. since April 15, 2013. Dr. Perlmutter also has been the President of Merck Research Laboratories since April 15, 2013. He serves as Science Partner at The Column Group LLC. Dr. Perlmutter was a Professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington in Seattle from January 1991 to January 1997. From 1981 to 1984, he was a Lecturer in the Division of Biology at the California Institute of Technology. Dr. Perlmutter served as Consultant of Amgen Inc. since February 2012. He served as an Executive Vice President of Research and Development at Amgen Inc. from January 2001 to February 2012, where he oversaw its worldwide research and development operations. He was responsible for the registration of ten significant new drugs including Sensipar, Prolia, Nplate and Xgeva. He also served as an Executive Vice President for Worldwide Discovery and Preclinical Research at Merck & Co., Inc. Dr. Perlmutter served as an Executive Vice President of Worldwide Basic Research and Preclinical Development of Merck Research Laboratories, from July 1999 to December 2000. He served as the President of the American Association of Immunologists. He served at Merck from February 1997 to 2001, including as an Executive Vice President of Merck Research Laboratories from February 1999 to July 1999 and Senior Vice President from February 1997 to January 1999. He served as an Investigator at the Howard Hughes Medical Institute at the University of Washington from October 1991 to January 1997. He serves as the Chairman of the Reed College Board of Trustees. He served as a Non-Executive Director of Heptares Therapeutics Ltd. since October 22, 2012. He has been a Director of The Irvington Institute for Immunological Research since 1997 and the Institute for Systems Biology since 1999. From May 1989 to January 1997, he was Founding Chairman of the Department of Immunology at the Howard Hughes Medical Institute at the University of Washington (Seattle). During this period, Dr. Perlmutter focused his scientific efforts on the elucidation of signaling pathways governing lymphocyte development and activation. He served as the Chairman of the Department of Immunology at the University of Washington from May 1989 to January 1997. He served as a Director of Immune Design Corp., since June 2012. He served as a Member of Scientific Advisory Board at Immune Design Corp. He served as a Director of StemCells Inc. from December 2000 to December 31, 2013. He served as Director of Ablynx NV from November 2012 to March 08, 2013. He is licensed to practice medicine in the State of California and the State of Washington. He pursued Clinical Training in Internal Medicine at the Massachusetts General Hospital and at the University of California at San Francisco. He graduated from Reed College in 1973 and received his MD and a Ph.D. from Washington University, St. Louis, Missouri in 1979. Dr. Roger M. Perlmutter, M.D., Ph.D., has been an Executive Vice President at Merck & Co., Inc. since April 15, 2013. Dr. Perlmutter also has been the President of Merck Research Laboratories since April 15, 2013. He serves as Science Partner at The Column Group LLC. Dr. Perlmutter was a Professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington in Seattle from January 1991 to January 1997. From 1981 to 1984, he was a Lecturer in the Division of Biology at the California Institute of Technology. Dr. Perlmutter served as Consultant of Amgen Inc. since February 2012. He served as an Executive Vice President of Research and Development at Amgen Inc. from January 2001 to February 2012, where he oversaw its worldwide research and development operations. He was responsible for the registration of ten significant new drugs including Sensipar, Prolia, Nplate and Xgeva. He also served as an Executive Vice President for Worldwide Discovery and Preclinical Research at Merck & Co., Inc. Dr. Perlmutter served as an Executive Vice President of Worldwide Basic Research and Preclinical Development of Merck Research Laboratories, from July 1999 to December 2000. He served as the President of the American Association of Immunologists. He served at Merck from February 1997 to 2001, including as an Executive Vice President of Merck Research Laboratories from February 1999 to July 1999 and Senior Vice President from February 1997 to January 1999. He served as an Investigator at the Howard Hughes Medical Institute at the University of Washington from October 1991 to January 1997. He serves as the Chairman of the Reed College Board of Trustees. He served as a Non-Executive Director of Heptares Therapeutics Ltd. since October 22, 2012. He has been a Director of The Irvington Institute for Immunological Research since 1997 and the Institute for Systems Biology since 1999. From May 1989 to January 1997, he was Founding Chairman of the Department of Immunology at the Howard Hughes Medical Institute at the University of Washington (Seattle). During this period, Dr. Perlmutter focused his scientific efforts on the elucidation of signaling pathways governing lymphocyte development and activation. He served as the Chairman of the Department of Immunology at the University of Washington from May 1989 to January 1997. He served as a Director of Immune Design Corp., since June 2012. He served as a Member of Scientific Advisory Board at Immune Design Corp. He served as a Director of StemCells Inc. from December 2000 to December 31, 2013. He served as Director of Ablynx NV from November 2012 to March 08, 2013. He is licensed to practice medicine in the State of California and the State of Washington. He pursued Clinical Training in Internal Medicine at the Massachusetts General Hospital and at the University of California at San Francisco. He graduated from Reed College in 1973 and received his MD and a Ph.D. from Washington University, St. Louis, Missouri in 1979.

Pathology